Ameliorating nervous systems disorders

Patent metadata

Field	Value
Publication number	US-10206953-B2
Application number	US-201514943916-A
Country	US
Kind code	B2
Filing date	Nov 17, 2015
Priority date	May 6, 2008
Publication date	Feb 19, 2019
Grant date	Feb 19, 2019

Abstract

The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.

First claim

What is claimed is:

1. A method for improving motor activity in the central nervous system (CNS) of a mammal having impaired motor activity, comprising:
transplanting medial ganglionic eminence (MGE) precursor cells into the CNS of the mammal.

2. The method of claim 1 , wherein the MGE precursor cells are transplanted into the brain of the mammal.

3. The method of claim 2 , wherein the MGE precursor cells are transplanted in or near the striatum.

4. The method of claim 1 , wherein the MGE precursor cells are transplanted into the spinal cord of the mammal.

5. The method of claim 1 , wherein the MGE precursor cells are transplanted by injection.

6. A method for improving motor function in a mammal affected with a nervous system disorder and in need of improved motor function, comprising:
transplanting medial ganglionic eminence (MGE) precursor cells into the nervous system of the mammal; and
allowing the MGE precursor cells to migrate and integrate into the nervous system of the mammal and change the balance of excitatory and inhibitory signals in the nervous system; and
assessing the mammal for an improvement in motor function.

7. The method of claim 6 , wherein the nervous system disorder is a central nervous system (CNS) disorder.

8. The method of claim 7 , wherein the CNS disorder is Parkinson's disease.

9. The method of claim 7 , wherein the MGE precursor cells are injected into the brain.

10. The method of claim 6 , wherein the nervous system disorder is a movement disorder.

11. The method of claim 6 , wherein the nervous system disorder is a nerve injury.

12. The method of claim 11 , wherein the nervous system disorder is spinal cord injury.

13. The method of claim 12 , wherein the MGE precursor cells are injected into the spinal cord.

14. A method for improving motor activity in a mammal having motor impairment and in need of improved motor activity, comprising:
transplanting medial ganglionic eminence (MGE) precursor cells into the nervous system of the mammal; and
allowing the MGE precursor cells to change the balance of excitatory and inhibitory signals in the nervous system of the mammal; and
assessing the mammal for an improvement in motor activity.

15. The method of claim 14 , wherein the MGE precursor cells are transplanted into the brain of the mammal.

16. The method of claim 15 , wherein the MGE precursor cells are transplanted in or near the striatum.

17. The method of claim 14 , wherein the MGE precursor cells are transplanted into the spinal cord of the mammal.

18. The method of claim 14 , wherein the MGE precursor cells are transplanted by injection.

Assignees

• Univ California

Inventors

• Kriegstein Arnold
• Rubenstein John L R
• Baraban Scott C
• Alvarez-Buylla Arturo

Classifications

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K35/30 Primary

  Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue · CPC title

• G01N2800/2842

  Pain, e.g. neuropathic pain, psychogenic pain · CPC title